IFNL3: A Protein Target for Cancer and Inflammation (G282617)

Target Name: IFNL3

NCBI ID: G282617

IFNL3

IFNL3: A Protein Target for Cancer and Inflammation

Interleukin-28C (IFNL3) is a protein that is expressed in a variety of tissues throughout the body. It is a cytokine that plays a role in the immune response and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the things that makes IFNL3 an attractive drug target is its ability to stimulate an immune response in the body. When the body is exposed to a pathogen or other potential harmful substance, IFNL3 is released and helps to stimulate an immune response to eliminate the invading substance. This is important for maintaining the health and integrity of the immune system.

IFNL3 has also been shown to play a role in the regulation of cellular processes that are important for cancer development. For example, studies have shown that IFNL3 can promote the growth and survival of cancer cells, and that it can also inhibit the death of cancer cells that have been treated with certain chemotherapy drugs. This suggests that IFNL3 may be a useful biomarker for the development and progression of cancer.

Another potential mechanism by which IFNL3 may be involved in the development of certain diseases is its role in the regulation of inflammation. Chronic inflammation, such as that caused by autoimmune disorders, has been implicated in the development of a wide range of diseases, including heart disease, diabetes, and neurodegenerative disorders. IFNL3 has been shown to be involved in the regulation of inflammatory responses, and it is possible that it may play a role in the regulation of chronic inflammation.

In addition to its potential role in the immune response and cancer development, IFNL3 is also of interest as a potential drug target because of its ability to stimulate a range of cellular processes. For example, studies have shown that IFNL3 can induce cell death, either through the production of reactive oxygen species (ROS) or through the inhibition of cellular signaling pathways. This suggests that IFNL3 may be a useful target for drugs that are designed to induce cell death, either by targeting cellular signaling pathways or by targeting DNA damage pathways.

Overall, IFNL3 is a protein that has been shown to play a range of roles in the immune response, cancer development, and inflammation. As a result, it is an attractive drug target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the mechanisms by which IFNL3 is involved in these processes, and to determine the best way to target it in order to develop new treatments for a wide range of diseases.

Protein Name: Interferon Lambda 3

Functions: Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression

The "IFNL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFNL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets